A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Rituximab is the first monoclonal antibody to receive approval in the treatment of cancer and
has been proven to lead to extended survival when administered intravenously in the treatment
of patients with systemic non-Hodgkin's lymphoma. We have previously demonstrated that a
small fraction of Rituximab administered intravenously is able to cross the
blood-brain-barrier into the brain.
We will test the idea that the direct injection into the cerebrospinal fluid of Rituximab, a
monoclonal antibody which attacks and kills lymphoma cells, is safe and when used in
combination with methotrexate in patients with recurrent brain and intraocular lymphoma.
We will also test the idea that the combination of rituximab plus methotrexate has activity
and is effective in the treatment of recurrent brain and intraocular lymphoma.